Results 51 to 60 of about 1,458 (171)
Human Absorption, Metabolism, and Excretion (hAME) Mass Balance Studies in Patients With Cancer
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Radiolabeled mass balance human studies are a critical component of clinical pharmacology programs supporting the development of new investigational drugs. These studies provide information about absorption, metabolism, and excretion (AME) of the parent drug and metabolite(s) in the human body and are normally conducted in healthy volunteers ...
Begoña de las Heras +9 more
wiley +1 more source
, 2023 Cell cycle checkpoint kinases serve as important therapeutic targets for various cancers. When they are inhibited by small molecules, checkpoint abrogation can induce cell death or further sensitize cancer cells to other genotoxic therapies. Particularly
Jeremy Fung (15158737) +9 more
core +1 more source
The role of Wee1 and Myt1 in breast cancer [PDF]
, 2020 To ensure faithful cell division, entry into mitosis must be inhibited in cells with damage or under-replicated DNA. Wee1 and Myt1 are two partially redundant kinases that inhibit mitotic entry through the phosphorylation of the Cdk1/cyclin B complex ...
Lewis, Cody Wayne
core +1 more source
BMJ Open, 2020 Introduction Patients with head and neck squamous cell carcinoma with locally advanced disease often require multimodality treatment with surgery, radiotherapy and/or chemotherapy. Adjuvant radiotherapy with concurrent chemotherapy is offered to patients
Martin Forster +15 more
doaj +1 more source
Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer
Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr +4 more
wiley +1 more source
, 2023 Cell cycle checkpoint kinases serve as important therapeutic targets for various cancers. When they are inhibited by small molecules, checkpoint abrogation can induce cell death or further sensitize cancer cells to other genotoxic therapies. Particularly
Jeremy Fung (15158737) +9 more
core +1 more source
HemaSphere, Volume 10, Issue 3, March 2026.Abstract TP53 mutations are found in over 50% of tumor types, including myeloproliferative neoplasms (MPNs). MPNs are characterized by a chronic phase, which may progress to secondary acute myeloid leukemia (sAML). Here, we discuss the physiological functions of p53 in hematopoiesis and its deregulation in MPNs.
Suzana da Silva‐Benedito +6 more
wiley +1 more source
, 2023 <div>AbstractPurpose:<p>Cyclin E (<i>CCNE1</i>) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted therapy.</p>Experimental Design:<p>Copy number and genomic sequencing data from The Cancer Genome Atlas and MD Anderson Cancer Center ...
Funda Meric-Bernstam +15 more
openaire +1 more source
MedComm – Oncology, Volume 5, Issue 1, March 2026.Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang +7 more
wiley +1 more source
Empower the potential of trastuzumab deruxtecan with novel combinations
, 2023 : Trastuzumab deruxtecan (T-DXd) is reshaping the therapeutic landscape of HER2-positive tumors. A recent article reports on the preclinical activity of the combination of T-DXd plus adavosertib, WEE1 kinase inhibitor, which promises to expand the use of
Marzia Del Re +5 more
core +1 more source